AIM ImmunoTech Inc (AMEX:AIM)
$ 0.2069 0.0008 (0.39%) Market Cap: 13.18 Mil Enterprise Value: 9.35 Mil PE Ratio: 0 PB Ratio: 4.14 GF Score: 40/100

AIM ImmunoTech greenlit to import chronic fatigue syndrome drug into Argentina Corporate Analyst Meeting Transcript

Jun 22, 2020 / NTS GMT
Release Date Price: $2.32 (-1.28%)
Christine Corrado
Proactive - Moderator

Hello, and welcome back to proactive New York. I'm Christine Corrado with me right now is Tom Equels CEO at AIM ImmunoTech. Tom, great to see you how are you?

Tom Equels
AIM ImmunoTech Inc. - CEO, President & Executive Vice Chairman

Good to see you again Christine. Looks great, the new hairstyle is wonderful.

Questions & Answers

Christine Corrado
Proactive - Moderator

Thank you very much. Very hot here in New York City, the company has gotten the green light to import Ampligen into Argentina to treat chronic fatigue syndrome. Can you just talk about what kind of work went into actually securing this?

Tom Equels
AIM ImmunoTech Inc. - CEO, President & Executive Vice Chairman

Well, we obtained the first ever. And this is in the work, governmental approval through a well-respected regulatory body, which is Argentina's FDA called ANMAT, commercial approval for Ampligen as a therapy for severe chronic fatigue syndrome.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot